Meptid

Meptazinol, the active ingredient in Meptid, is an opioid analgesic (phenylpiperidine) presented as an oral dosage form for oral use. It is employed to manage moderate acute pain, including postoperative and obstetric pain, in adult patients. The drug provides analgesia with a ceiling effect on respiratory depression, reducing risk of severe respiratory compromise.

GNH USA supplies Meptid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our quality‑assured manufacturing meets EU standards for safety and efficacy.

Meptazinol is used for pain management in the opioid analgesic pathway.

- Moderate acute pain: provides effective analgesia for short‑term severe pain episodes. - Post‑operative pain: reduces pain following surgical procedures. - Obstetric analgesia: alleviates pain during labor and delivery.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Dizziness: transient light‑headedness. - Constipation: reduced bowel motility. - Sedation: drowsiness or reduced alertness.

Serious or Rare Side Effects: - Respiratory depression: reduced breathing effort, especially with overdose. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, swelling, or anaphylaxis.

Meptid should be prescribed after careful assessment of pain severity and opioid suitability.

- Assess pain severity before prescribing: ensure pain is moderate and opioid appropriate. - Monitor for signs of respiratory depression: especially during initial dosing. - Avoid use in patients with known hypersensitivity to phenylpiperidines. - Use caution in elderly or renal/hepatic impairment: increase monitoring frequency. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Meptid may interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid): - Concomitant use with other opioids: risk of additive respiratory depression. - Combined with CNS depressants (benzodiazepines, barbiturates): increased sedation and respiratory risk. - MAO inhibitors: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase serotonin syndrome risk. - Anticholinergic agents: can worsen constipation. - Alcohol: enhances central nervous system depression.